MRI dye tracked in urine: new study aims to see how fast it clears

NCT ID NCT06191731

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Régional Metz-Thionville Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how quickly gadolinium, a contrast agent used in some MRIs, leaves the body through urine. Researchers will collect urine samples from 60 adults before and up to 2.5 hours after their MRI. The goal is to better understand the body's elimination of this substance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gadolinium-based contrast agents
What this could lead to: If successful, this could help doctors understand how quickly the body clears gadolinium after an MRI, which may improve safety guidelines.
What could go wrong: This is a small, early observational study with only 60 participants. It measures urine levels, not health outcomes, so it won't directly change treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAGNETIC RESONANCE IMAGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAGNETIC RESONANCE IMAGING

Contacts and locations

Locations

CHR Metz-Thionville / Hopital Bel Air
NOT_YET_RECRUITING

Thionville, France
CHR Metz-Thionville/Hopital de Mercy
RECRUITING

Metz, Grand Est, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.